Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Stephan Herbertz, J Scott Sawyer, Anja J Stauber, Ivelina Gueorguieva, Kyla E Driscoll, Shawn T Estrem, Ann L Cleverly, Durisala Desaiah, Susan C Guba, Karim A Benhadji, Christopher A Slapak & Michael M Lahn. (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Design, Development and Therapy 9, pages 4479-4499.
Read now
Read now
Jose Baselga, Mace L. Rothenberg, Josep Tabernero, Joan Seoane, Thomas Daly, Ann Cleverly, Brandi Berry, Susanne K. Rhoades, Chad A. Ray, Jeffrey Fill, Daphne L. Farrington, Lisa Anne Wallace, Jonathan M. Yingling, Michael Lahn, Carlos Arteaga & Michael Carducci. (2008) TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers 13:2, pages 217-236.
Read now
Read now
Articles from other publishers (15)
Rongrong Ge & Gavin M. Huang. (2023) Targeting transforming growth factor beta signaling in metastatic osteosarcoma. Journal of Bone Oncology 43, pages 100513.
Crossref
Crossref
Hideto Taga, Tsunao Kishida, Yuta Inoue, Kenta Yamamoto, Shin-ichiro Kotani, Tsujimoto Masashi, Osamu Ukimura & Osam Mazda. (2023) TGF-β inhibitor treatment of H₂O₂-induced cystitis models provides biochemical mechanism for elucidating interstitial cystitis/painful bladder syndrome patients. PLOS ONE 18:11, pages e0293983.
Crossref
Crossref
Yujia Li, Weiguo Fan, Frederik Link, Sai Wang & Steven Dooley. (2022) Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease. JHEP Reports 4:2, pages 100397.
Crossref
Crossref
Sijia Liu, Jiang Ren & Peter ten Dijke. (2021) Targeting TGFβ signal transduction for cancer therapy. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Brendan M Giles, Timothy T Underwood, Karim A Benhadji, Diana K S Nelson, Lisa M Grobeck, Boris Lin, Shuaicheng Wang, Jeffrey A Fill, Michael Man, Kelly R Pitts & Alison Bamberg. (2018) Analytical Characterization of an Enzyme-Linked Immunosorbent Assay for the Measurement of Transforming Growth Factor β1 in Human Plasma. The Journal of Applied Laboratory Medicine 3:2, pages 200-212.
Crossref
Crossref
Jonathan M. Yingling, William T. McMillen, Lei Yan, Huocong Huang, J. Scott Sawyer, Jeremy Graff, David K. Clawson, Karen S. Britt, Bryan D. Anderson, Douglas W. Beight, Durisala Desaiah, Michael M. Lahn, Karim A. Benhadji, Maria J. Lallena, Rikke B. Holmgaard, Xiaohong Xu, Faming Zhang, Jason R. Manro, Philip W. Iversen, Chandrasekar V. Iyer, Rolf A. Brekken, Michael D. Kalos & Kyla E. Driscoll. (2017) Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget 9:6, pages 6659-6677.
Crossref
Crossref
Alexander E. Kudinov & Tim N. Beck. 2018. Molecular Determinants of Head and Neck Cancer. Molecular Determinants of Head and Neck Cancer
89
115
.
Belinda J. Thomas, Keiko Kan-o, Kate L. Loveland, Jack A. Elias & Philip G. Bardin. (2016) In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β. American Journal of Respiratory Cell and Molecular Biology 55:6, pages 759-766.
Crossref
Crossref
Nan Sun, Ayumu Taguchi & Samir Hanash. (2016) Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. Journal of Clinical Medicine 5:12, pages 109.
Crossref
Crossref
Jordi Rodón, Michael Carducci, Juan M. Sepulveda-Sánchez, Analía Azaro, Emiliano Calvo, Joan Seoane, Irene Braña, Elisabet Sicart, Ivelina Gueorguieva, Ann Cleverly, N. Sokalingum Pillay, Durisala Desaiah, Shawn T. Estrem, Luis Paz-Ares, Matthias Holdhoff, Jaishri Blakeley, Michael M. Lahn & Jose Baselga. (2014) Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Investigational New Drugs 33:2, pages 357-370.
Crossref
Crossref
H.H. Nienhuis, S.B.M. Gaykema, H. Timmer-Bosscha, M. Jalving, A.H. Brouwers, M.N. Lub-de Hooge, B. van der Vegt, B. Overmoyer, E.G.E. de Vries & C.P. Schröder. (2015) Targeting breast cancer through its microenvironment: Current status of preclinical and clinical research in finding relevant targets. Pharmacology & Therapeutics 147, pages 63-79.
Crossref
Crossref
Rosemary J. Akhurst & Akiko Hata. (2012) Targeting the TGFβ signalling pathway in disease. Nature Reviews Drug Discovery 11:10, pages 790-811.
Crossref
Crossref
Marlous Arjaans, Thijs H. Oude Munnink, Hetty Timmer-Bosscha, Michael Reiss, Annemiek M.E. Walenkamp, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries & Carolina P. Schröder. (2012) Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. Pharmacology & Therapeutics 135:2, pages 123-132.
Crossref
Crossref
Ying Chen, Guanzhen Yu, Danghui Yu & Minghua Zhu. (2010) PKCα-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-β1. Journal of Experimental & Clinical Cancer Research 29:1.
Crossref
Crossref
Antoinette R. Tan, Gabriela Alexe & Michael Reiss. (2008) Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?. Breast Cancer Research and Treatment 115:3, pages 453-495.
Crossref
Crossref